FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes dominant service provider in sub-Saharan Africa
DURHAM, NORTH CAROLINA — FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO.
FHI Clinical will maintain its global headquarters in Durham, NC with additional operations in 12 countries. The company now employs approximately 450 staff, with approximately 285 employees based in East and West Africa.
About FHI Clinical
FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world. Benefitting from our 50+ year history of clinical research, our team of approximately 450 global staff has worked on studies in more than 70 countries. As problem solvers, forward thinkers and on-the-ground members of those communities, we are dedicated to helping you find solutions to the research challenges that have kept life-saving therapies from at-risk populations. Visit fhiclinical.com or contact us at firstname.lastname@example.org or 919.321.3321 to learn how we can put our diverse clinical and operational expertise to work for you.